Wanbury Ltd Launches Two New APIs, Plans Further Expansion

Wanbury Ltd, a pharmaceutical company with a strong presence in the global API market, has announced the launch of two new active pharmaceutical ingredients (APIs): Dextromethorphan and Ketamine. The company plans to accelerate growth by introducing three additional APIs in the near term. Wanbury's API portfolio currently includes seven commercially available products, with five more in the pipeline. The company's Q3 FY25 results showed a temporary impact on revenue and profitability due to a 30-day shutdown of its Tanuku facility for upgradation and capacity expansion. Despite this, Wanbury continues to strengthen its API portfolio by expanding its customer base and broadening its geographic presence.

Sources: BSE, NSE, Wanbury Ltd Official Website